Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03815058
Title A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.
Acronym IMCODE001
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | ESP | DEU | BEL | AUS


No variant requirements are available.